Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioMed rTSST-1 Variant Vaccine in Healthy Adults
NCT02971670Phase 1Completed
- Sponsor
- Biomedizinische Forschung
- Start
- Oct 2015
- Primary completion
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, single-blind trial of rTSST-1 variant vaccine in toxic shock syndrome (TSS) (4 arms), sponsored by Biomedizinische Forschung. Primary endpoints: Number of Participants With Adverse Events as a Measure of Safety at 6 months and Persistence of TSST-1 Antibodies. Started Oct 2015; status: completed.
02
Drugs
rTSST-1 variant vaccine
03
Conditions
toxic shock syndrome (TSS)
Beyond the preview
Go deeper on NCT02971670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971670.